Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inovio Pharmaceuticals (INO – Research Report), Ocuphire Pharma (OCUP – Research Report) and Artivion (AORT – Research Report).
Inovio Pharmaceuticals (INO)
H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Inovio Pharmaceuticals today. The company’s shares closed last Thursday at $1.51, close to its 52-week low of $1.38.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Inovio Pharmaceuticals is a Moderate Sell with an average price target of $2.00.
See the top stocks recommended by analysts >>
Ocuphire Pharma (OCUP)
H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Ocuphire Pharma today and set a price target of $20.00. The company’s shares closed last Thursday at $3.83.
According to TipRanks.com, Caufield is a 5-star analyst with an average return of
Currently, the analyst consensus on Ocuphire Pharma is a Moderate Buy with an average price target of $18.00.
Artivion (AORT)
In a report released today, Michael Matson from Needham reiterated a Buy rating on Artivion, with a price target of $23.00. The company’s shares closed last Thursday at $13.20.
According to TipRanks.com, Matson is a 3-star analyst with an average return of
Currently, the analyst consensus on Artivion is a Moderate Buy with an average price target of $23.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INO:
